Lantheus trades as part of the healthcare sector and trades as part of the medical diagnostics and research industry. The company CEO is Mary Anne Heino. Lantheus Inc develops diagnostic products for the healthcare sector. Its chief product is imaging agents used by physicians in diagnostic procedures such as cardiac ultrasounds and X-ray imaging.



Previous Intraday Performance:

The LNTH shares had a previous change of -2.55% which opened at 26.14 and closed at 25.24. It moved to an intraday high of 26.32 and a low of 24.46.

SeekingAlpha:  Lantheus teams up with NanoMab in cancer radiopharmaceuticals

Historical Performance:

Over the last five trading days, LNTH shares returned -0.16% and in the past 30 trading days it returned 4.47%. Over three months, it changed 5.56%. In one year it has changed 74.67% and within that year its 52 week high was 26.40 and its 52 week low was 12.59. LNTH stock is 100.48% above its 52 week low.

Our calculations result in a 200 day moving average of 19.14 and a 50 day moving average of 24.89. Right now, LNTH stock is trading 31.87% above its 200 day moving average.

SeekingAlpha:  Lantheus teams up with NanoMab in cancer radiopharmaceuticals

Liquidity:

The company has a market cap of $979.8m with 38.8m shares outstanding and a float of 36.9m shares. Trading volume was 420,934 shares and has experienced an average volume of 436,235 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.

Earnings:

The last annual reported EPS for Lantheus was 1.04 which ended on 31st of December 2018, which according to the previous close, that is a PE of 24.27. Based on 2 analyst estimates, the consensus EPS for the next quarter is 0.27. The trailing twelve month EPS reported is 0.96 (trailing twelve month diluted EPS is 1.08).

Below was the last reported quarterly diluted earnings per share:

1stQtr 2019Reported 04-30-2019: 0.25
4thQtr 2018Reported 02-19-2019: 0.34
3rdQtr 2018Reported 10-30-2018: 0.24
2ndQtr 2018Reported 08-01-2018: 0.25
1stQtr 2018Reported 05-02-2018: 0.21

Base on our calculations, the intrinsic value per share is 28.19, which means it might be undervalued and has a margin of safety of 10.47%.

The long-term trend of the EPS is an important number as it indicates the present value of Lantheus; the EPS growth rate, as it is typically called, is usually expressed as a percentage, which at this time is hard to estimate, but revenue growth has been 3.00% over the last twelve months.



Indicators Also to Watch:

The beta was calculated to be 1.39.

SeekingAlpha:  HC2 Holdings, Inc. 2019 Q1 – Results – Earnings Call Slides

Fundamental Numbers:

Based on last reported financials, the company’s return on assets is 10.54%, profit margin is 12.26%, price-to-sales is 2.90 and price-to-book is 12.08.

Company Score Card:

Results are out of six:
 2  : Growth Expectations Result
 4  : Financial Safety Result
 2  : Past Performance Result
 1  : Valuation Result
 0  : Dividend Safety Result
 2  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).

LEAVE A REPLY

Please enter your comment!
Please enter your name here